The Real World Experience with Lecanemab: A US Case Study

Abstract

Background: Lecanemab is the first anti‐amyloid monoclonal antibody with full FDA‐approval to treat Alzheimer's disease (AD), a chronic and irreversible neurodegenerative disorder that affects cognitive function, leads to progressive loss of autonomy and the ability to perform activities of daily living.

The paper